European Multicenter Study on Surgical Management of Advanced Thyroid Cancer (ATCEU)

Institute of Hospitalization and Scientific Care (IRCCS)

Status: Enrolling

Conditions: Thyroid Cancer, Papillary; Thyroid Carcinoma; Thyroid Cancer, Follicular; Thyroid Medullary Carcinoma; Thyroid Neoplasms; Thyroid Cancer; Anaplastic Thyroid Cancer

Treatments: Procedure: Thyroidectomy with or without lymphadenectomy or multivisceral resection

Study type: Observational

Funder types: Other

Identifiers

NCT05796960

4999

Details and patient eligibility

About

The main aim of the study is to evaluate peri-operative surgical characteristics, operation extent, postoperative morbidity, and outcomes in patients undergoing surgery for advanced thyroid cancer in different European centers using the EUROCRINE® database.

Full description

The incidence of thyroid cancer has risen exponentially over the last decades among developed countries. Even though this is mainly attributed to small well differentiated carcinomas (DTC) with excellent prognosis, the rates of advanced disease have also elevated. While the characteristics of advanced thyroid cancer are intuitively recognized by experienced surgeons of the field, a common definition among scientific societies is yet to be reached. The four main features of advanced cancer are locally and regionally advanced disease, distant metastasis, and recurrence. Guidelines for the optimal treatment of advanced disease are mainly included in the broader guidelines of each cancer subtype, such as the American Thyroid Association (ATA) guidelines for DTC, Medullary Thyroid Carcinoma (MTC) and most recently Anaplastic Thyroid Carcinoma (ATC). In the European setting, the European Society for Medical Oncology (ESMO) 2019 guidelines on thyroid cancer include a subsection for the management of advanced disease of each thyroid cancer type. A common limitation among published guidelines is the moderate to low level of evidence upon which the advanced disease recommendations are based; however, broad consensus has been reached regarding the paramount importance of surgery if an R0/R1 resection is achievable. Recently, new advances in targeted therapy guided by genetic alterations found in the tumor have provided new treatment options for patients; therefore, latest guidelines encourage the inclusion of patients with advanced disease in these clinical trials. Finally, neoadjuvant therapy modalities are constantly gaining ground with promising results allowing a greater portion of patients to benefit from surgery.

Enrollment: 3,917 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All adult (18 years old and older) patients
• underwent surgery
• final histology of advanced thyroid carcinoma
• among European centers that participate in the Eurocrine® database between 2015 and 2021

Exclusion criteria

• Patients <18 years old

Trial design

3,917 participants in 1 patient group

Surgical operations for advanced thyroid cancer

Description:

All adult (18 years old and older) patients registered in EUROCRINE® database with stage IV thyroid cancer, M1, N1b, or T3b and above will be included

Treatment:

Procedure: Thyroidectomy with or without lymphadenectomy or multivisceral resection